Down-regulation of HMGB1 expression by shRNA constructs inhibits the bioactivity of urothelial carcinoma cell lines via the NF-kappa B pathway

作者：Huang, Zhichao; Zhong, Zhaohui; Zhang, Lei; Wang, Xinjun; Xu, Ran; Zhu, Liang; Wang, Zijian; Hu, Shanbiao; Zhao, Xiaokun^*

来源：Scientific Reports, 2015, 5(1): 12807.

DOI：10.1038/srep12807

• GROUP BOX 1
• MOBILITY GROUP BOX-1
• END-PRODUCTS RAGE
• GENE-EXPRESSION
• CHROMATIN PROTEIN
• POOR-PROGNOSIS
• CANCER
• RECEPTOR
• BINDING
• DNA

The high mobility group box 1 (HMGB1), which is a highly conserved and evolutionarily non-histone nuclear protein, has been shown to associate with a variety of biological important processes, such as transcription, DNA repair, differentiation, and extracellular signalling. High HMGB1 expression has been reported in many cancers, such as prostate, kidney, ovarian, and gastric cancer. However, there have been few studies of the function of HMGB1 in the malignant biological behaviour of bladder urothelial carcinoma (BUC), and the potential mechanism of HMGB1 in the pathogenesis of BUC remains unclear. Thus, in this study, we constructed plasmid vectors that are capable of synthesizing specific shRNAs targeting HMGB1 and transfected them into BUC cells to persistently suppress the endogenous gene expression of HMGB1. The expression of HMGB1, the bioactivity of BUC cells, including proliferation, apoptosis, cell cycle distribution, migration and invasion, and the effects of HMGB1 knockdown on downstream signalling pathways were investigated. Our data suggest that HMGB1 promotes the malignant biological behaviour of BUC, and that this effect may be partially mediated by the NF-kappa B signalling pathway. HMGB1 may serve as a potential therapeutic target for BUC in the future.

• 出版日期2015-8-4
• 单位厦门大学